Hong Kong has been severely affected by severe acute respiratory syndrome (SARS). Contact in households and healthcare settings is thought to be important for transmission, putting children at particular risk. Most data so far, however, have been for adults. We prospectively followed up the first ten children with SARS managed during the early phase of the epidemic in Hong Kong. All the children had been in close contact with infected adults. Persistent fever, cough, progressive radiographic changes of chest and lymphopenia were noted in all patients. The children were treated with high-dose ribavirin, oral prednisolone, or intravenous methylprednisolone, with no short-term adverse effects. Four teenagers required oxygen therapy and two needed assisted ventilation. None of the younger children required oxygen supplementation. Compared with adults and teenagers, SARS seems to have a less aggressive clinical course in younger children.
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Since late February, 2003, WHO has received reports of outbreaks of a severe form of atypical pneumonia in Vietnam, Hong Kong, and Singapore. Hong Kong is the most severely affected city. WHO has referred to this unusual form of severe pneumonia as severe acute respiratory syndrome (SARS). 1 The surveillance case definition of SARS is: history of high fever (>38ЊC); one or more respiratory symptoms, including cough, shortness of breath, and difficulty breathing; and close contact within 10 days before onset of symptoms with a person who has been diagnosed with SARS, history of travel within 10 days before onset before symptoms to an area with reported foci of SARS transmission, or both. 1 Household contact and contacts in health-care settings are believed to be important routes of transmission. 2, 3 This transmission route could put children at particular risk, but most data available so far have been in adults. We therefore decided to report our experience in treating children with SARS.
Between March 13 and 28, 2003, ten children with suspected SARS were admitted to and managed at the Prince of Wales and Princess Margaret Hospitals, Hong Kong. We prospectively followed up the clinical, laboratory, and radiological profiles and treatment outcomes of these children. Microbiological investigations were done to detect common bacterial and viral pathogens associated with communityacquired pneumonia.
We treated all patients with combined corticosteroids, antivirals, and antibacterial agents. Intravenous cefotaxime, oral clarithromycin, and oral ribavirin (40 mg/kg daily, given in two or three doses) were started if a diagnosis of SARS was suspected on admission. Oral prednisolone (0·5 mg/kg daily at Prince of Wales Hospital, and 2·0 mg/kg daily at Princess Margaret Hospital) was added if fever persisted after 48 h. In addition, we treated patients who had moderate symptoms of high fluctuating fever and notable malaise with intravenous ribavirin (20 mg/kg daily, given in three doses) and hydrocortisone (2 mg/kg every 6 h) immediately after admission. For patients who had persistent fever and progressive worsening clinically or radiologically, we used pulse intravenous methylprednisolone (10-20 mg/kg). Ribavirin was administered for 1-2 weeks and corticosteroid dose was tapered over 2-4 weeks.
All children satisfied the WHO case definition for SARS and all had been in close contact with infected adults. The demographic, clinical, and laboratory data are shown in the table. Fever was a consistent symptom in all children, and lasted for a median duration of 6 days (range 3-11). There was no clinically significant drop in haemoglobin concentrations during treatment with ribavirin. In eight patients, corticosteroid was added to the regimen when fever did not subside. Pulse methylprednisolone was given to one young child (patient 2) and four teenagers (patients 6-9). Within 2 days of corticosteroid administration, all but one patient (patient 9) became afebrile. The same four teenagers developed respiratory distress and oxygen desaturation on day 5, 4, 6 and 7, respectively, after the onset of fever. These children were placed under strict isolation for 21 days and became asymptomatic before discharge.
Nine children had abnormal chest radiographs on presentation. The primary abnormality was air-space opacification. Of the five children aged 12 years or younger (patients 1-5), four presented with focal segmental consolidation. Patient 2 had ill-defined patchy consolidation, but CT of the thorax showed multifocal air-space consolidation. All these patients had mild progressive consolidative change on serial chest radiographs but complete resolution was achieved within 14 days. The typical radiographic changes in one patient are shown in the figure. Three of the five teenagers (patients 7-9) presented with bilateral lower-lobe opacification at presentation, which progressed rapidly within days. Despite clinical improvement, these consolidative changes persisted into the 2nd week of the illness. Patient 10 showed no abnormality on chest radiography at presentation, but high-resolution CT confirmed focal consolidation in the right lower lobe. In CT of the thorax in patients 2 and 6, the characteristic features of peripheral and alveolar opacities simulated the radiological appearances of bronchiolitis obliterans organising pneumonia. Four teenagers required supplemental oxygen, one required bi-level positive airway pressure and intermittent positive-pressure ventilation. Respiratory distress developed 4-7 days after presentation.
Lymphopenia (0·3-3·0ϫ10 9 /L) was reported in all patients, but the teenagers were generally more severely affected than the younger children. Lymphopenia mostly occurred between days 3 and 7, after the onset of fever. No bacteria, fungi, mycoplasma, chlamydia, or common respiratory viruses were detected by the laboratory investigations. Coronavirus was isolated by viral culture from the nasopharyngeal aspirates of patients 2 and 3. Reverse-transcriptase PCR targeting the novel coronavirus present in the nasopharyngeal aspirate samples was positive in four of six children tested (patients 1, 7, 9, and 10).
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Clinical presentations and outcome of severe acute respiratory syndrome in children it was more severe among the teenage children. However, since young children normally have higher lymphocyte counts than adults, the interpretation of results must take into account the patients' ages. 4 Furthermore, lymphopenia frequently resolves when the disease is improving. We adopted a treatment regimen of ribavirin and steroids similar to that used in adult SARS patients. 2, 3 Ribavirin is a broad-spectrum antiviral agent and has been used for treatment of severe respiratory syncytial virus infection in We noted two distinct patterns of clinical presentation among the children we studied. Teenage patients presented with symptoms of malaise, myalgia, chill, and rigor similar to those of adults, 2,3 whereas the younger children presented mainly with cough and runny nose, and none had chills, rigor, or myalgia. The clinical course was much milder and shorter among younger patients, and radiological changes were milder and generally resolved more quickly than in the teenagers. All paediatric patients had clinically important lymphopenia, 3 Clinical features and treatment outcomes among SARS children children. 5 Among our patients, short-term use of high-dose ribavirin was well tolerated and had no major short-term adverse effects such as severe haemolytic anaemia. In addition, high-dose corticosteroid was used in combination with the antiviral agent because severe immune-mediated damage of lung tissue was reported in postmortem examination of SARS patients. 3 Eight of the ten children had been attending school at the time of presentation. There was no evidence that they had spread the infection to their classmates. This finding is in sharp contrast to the experience reported among adults that SARS carries a very high infectivity rate. 2, 3 At the time of our study, 22 adults had died in Hong Kong. 3 During the study period, around 30 children were suspected as having SARS in Hong Kong. So far, no child has died. Our preliminary findings suggest that young children develop a milder form of the disease with a less-aggressive clinical course than do teenagers and adults.
Serial chest radiographs of patient 5, who presented with fever and cough A=ill-defined air-space consolidation in periphery of right upper lobe and abutting horizontal fissure. B=Increased consolidation in right upper zone on day 5.
Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer

Thomas Guttuso Jr, Joseph Roscoe, Jennifer Griggs
In an anecdotal report, complete resolution of chemotherapyinduced nausea was seen in a patient with breast cancer, after she was placed on the anticonvulsant gabapentin. On this basis, we did an open-label study in which oral gabapentin 300 mg thrice daily was given for every other chemotherapy treatment in nine patients with breast cancer. Six of the nine reported at least a three-point improvement in peak delayed nausea (on an eight-point nausea scale), and three patients had complete resolution of nausea when taking gabapentin. This preliminary evidence shows that gabapentin might have a role in treatment of chemotherapy-induced nausea.
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Delayed onset of nausea induced by chemotherapy remains a problem for about half of patients receiving moderately emetogenic chemotherapy, despite preventive treatment with a serotonin antagonist and dexamethasone. 1 We describe an open-label study of therapy with the anticonvulsant gabapentin for acute (within 24 h) and delayed onset (days 2-5) nausea induced by chemotherapy.
The initial report came from a 59-year-old woman who began to have hot flushes soon after stopping oral oestrogen therapy because of newly diagnosed breast cancer. Chemotherapy consisting of doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 was given four times, the treatments separated by 3 weeks. Ondansetron 10 mg and dexamethasone 10 mg were given before each treatment. The patient reported severe nausea after the first two chemotherapy treatments. Prochlorperazine 10 mg taken thrice daily as required was ineffective. Midway between the second and third chemotherapy treatments, oral gabapentin 300 mg thrice daily was started for treatment of the patient's hot flushes. Within 2 days, all such symptoms had resolved. Unexpectedly, she had no nausea after either the third or the fourth chemotherapy treatments. No other medication changes had been made.
We did an open-label study examining the effects of oral gabapentin 300 mg thrice daily on chemotherapy-induced nausea in breast-cancer patients who had not previously
